Tiziana Triulzi

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (15)

Lucia Sfondrini

Associate Professor In General Pathology and Immunology

University of Milan

ITALY

View details

Simone Guglielmetti

Associate Professor

University of Milan

ITALY

View details

paolo verderio

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Sherene Loi

University of Melbourne

AUSTRALIA

View details

Elda Tagliabue

Head of Molecular Targeting Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

NICOLETTA GAGLIANO

Università degli Studi di Torino

ITALY

View details

loris de cecco

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

MARTINA DI MODICA

Open University

UNITED KINGDOM

View details

Sokol Kosta

Associate Professor at Aalborg University

Aalborg University

DENMARK

View details

Serenella Pupa

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Juan Rafael de la Haba Rodríguez

Profesor Titular

Universidad de Córdoba

SPAIN

View details

Michele Sommariva

Assistant Professor

Università degli Studi di Torino

ITALY

View details

Serena Di Cosimo

Open University

UNITED KINGDOM

View details

Federico Ambrogi

Associate Professor

Università degli Studi di Torino

ITALY

View details

Antonia Martinetti

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tiziana Triulzi

Research Interests

Explore related searches

Contact this professor

Articles (13)

SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness

The Emerging Role of the Microbiota in Breast Cancer Progression

The EU-funded I<sup>3</sup>LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: A multiomics analysis

Live or Heat-Killed <i>Lactobacillus rhamnosus </i>Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer

Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness.

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine.

Collaborators (15)

Lucia Sfondrini

Simone Guglielmetti

paolo verderio

Sherene Loi

Elda Tagliabue

NICOLETTA GAGLIANO

loris de cecco

MARTINA DI MODICA

Sokol Kosta

Serenella Pupa

Juan Rafael de la Haba Rodríguez

Michele Sommariva

Serena Di Cosimo

Federico Ambrogi

Antonia Martinetti

Make your next move.

Tiziana Triulzi

Research Interests

Explore related searches

Contact this professor

Articles (13)

SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness

The Emerging Role of the Microbiota in Breast Cancer Progression

The EU-funded I<sup>3</sup>LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 &lt;50%: A multiomics analysis

Live or Heat-Killed <i>Lactobacillus rhamnosus </i>Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer

Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness.

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine.

Collaborators (15)

Lucia Sfondrini

Simone Guglielmetti

paolo verderio

Sherene Loi

Elda Tagliabue

NICOLETTA GAGLIANO

loris de cecco

MARTINA DI MODICA

Sokol Kosta

Serenella Pupa

Juan Rafael de la Haba Rodríguez

Michele Sommariva

Serena Di Cosimo

Federico Ambrogi

Antonia Martinetti

Make your next move.

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: A multiomics analysis